Biopharmaceuticals : (Record no. 17172)

MARC details
000 -LEADER
fixed length control field 04507cam a2200529Ki 4500
001 - CONTROL NUMBER
control field 9781351013154
003 - CONTROL NUMBER IDENTIFIER
control field FlBoTFG
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220724194410.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr cnu---unuuu
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201211s2021 flu ob 001 0 eng
040 ## - CATALOGING SOURCE
Original cataloging agency OCoLC-P
Language of cataloging eng
Description conventions rda
Transcribing agency OCoLC-P
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781351013154
Qualifying information electronic book bk
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1351013157
Qualifying information electronic book bk
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781351013130
Qualifying information (electronic bk. : EPUB)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1351013130
Qualifying information (electronic bk. : EPUB)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781351013147
Qualifying information (electronic bk. : PDF)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1351013149
Qualifying information (electronic bk. : PDF)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781351013123
Qualifying information (electronic bk. : Mobipocket)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1351013122
Qualifying information (electronic bk. : Mobipocket)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN 9780815347774
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN 0815347774
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)1227044579
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC-P)1227044579
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RM301.4
Item number .B44 2021
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 008000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 071000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code TDCW
Source bicssc
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615.7
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Behera, Basanta Kumara,
Relator term author.
245 10 - TITLE STATEMENT
Title Biopharmaceuticals :
Remainder of title challenges and opportunities /
Statement of responsibility, etc. authored by Basanta Kumara Behera.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Boca Raton :
Name of producer, publisher, distributor, manufacturer CRC Press,
Date of production, publication, distribution, manufacture, or copyright notice 2021.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource :
Other physical details illustrations
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Biopharmaceutical : A New Confront -- Biopharmaceutical Production -- Transitioning from Pharmaceutical to Biopharmaceutical -- Biopharmaceutical from Animal cells -- Plant Biomolecules and Therapeutic -- Biosimilar -- Biopharmaceutical Supply Chain Management.
520 ## - SUMMARY, ETC.
Summary, etc. "This book highlights how traditional microbial process technology has been upgraded for the production of biologic drugs, and evolution of manufacturing process to meet the global market demand with quality products under the guide lines of internally recognised regulatory bodies. This piece of work also carries information on how armed with deeper understanding of life threatening disease, the biopharmaceutical companies or life sciences industries have developed royal scientific heritage of understanding by developing formal and informal partnerships with researchers in institute, universities and other R&D organisation to fulfil the promise of timely quality production with perfect safety and security. One of the most interesting aspects of this piece of work is the conceptual development of personalized medicine (or precision medicine) to get the right treatment to the right patient at the right dose at the earlier stage of development of any inherited disease. Besides this, it also high lights on the most challenging aspects of modern biopharmaceutical science focusing on the most burning topics like design and development of biologic drugs; use of diversified groups of host cells belonging from animals, plants, microbes, insects and mammals; stem cell therapy and gene therapy; supply chain management of biopharmaceuticals; and the future scope of biopharmaceutical industry development. This book is a latest resource for a wide circle of scientists, students and researchers involve in understanding and implementing the knowledge of biopharmaceutical to develop biologics for life saving drugs, and bring awareness on personalized medicines that can potentially offer patients faster diagnoses, fewer side effects and better outcomes. Features: Explains how the traditional cells culture methodology has been changed to fully continuous or partially continuous process. It explains how to design and fabricate living organs of body by 3D bioprinting technology. It focuses on how a biopharmaceutical company confront with various problems of regulatory bodies, and develop innovative biologic drugs. It narrates in detail the update information on stem cell therapy and gene therapy. It explains the development strategies and clinical significance of bio-similars and bio-betters. It high lights on supply chain management of biopharmaceuticals"--
588 ## - SOURCE OF DESCRIPTION NOTE
Source of description note OCLC-licensed vendor bibliographic record.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pharmaceutical biotechnology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biopharmaceutics.
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element MEDICAL / Biochemistry
Source of heading or term bisacsh
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element MEDICAL / Pharmacology
Source of heading or term bisacsh
856 40 - ELECTRONIC LOCATION AND ACCESS
Materials specified Read Online
Uniform Resource Identifier <a href="https://www.taylorfrancis.com/books/9781351013154">https://www.taylorfrancis.com/books/9781351013154</a>
856 42 - ELECTRONIC LOCATION AND ACCESS
Materials specified OCLC metadata license agreement
Uniform Resource Identifier <a href="http://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf">http://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Library of Congress Classification
Koha item type eBook

No items available.

To Reach Us

0206993118
amiu.library@amref.ac.ke

Our Location

Lang’ata Road, opposite Wilson Airport
PO Box 27691 – 00506,   Nairobi, Kenya

Social Networks

Powered by Koha